Last reviewed · How we verify
NCT07359430
Deep Phenotyping of CIndU
trial in Skin Diseases in 40 participants. Currently enrolling.
1 June 2026
Quick facts
| Lead sponsor | Centre for Human Drug Research, Netherlands |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 40 |
| Start date | 21 January 2025 |
| Primary completion | 1 June 2026 |
| Estimated completion | 1 June 2026 |
| Sites | 3 locations across Netherlands |
Conditions studied
- Skin Diseases — all drugs for Skin Diseases →
- Angio-Oedema and/or Urticaria — all drugs for Angio-Oedema and/or Urticaria →
Sponsor
Centre for Human Drug Research, Netherlands — full company profile →
Who can join
18 and older, any sex, with Skin Diseases or Angio-Oedema and/or Urticaria. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Chronic inducible urticaria (CIndU) is a group of skin disorders defined by recurrent itchy or burning wheals or angioedema that recur for more than six weeks with a specific triggering factor. This is different from chronic spontaneous urticaria which does not have a specific triggering factor. CIndU is subclassified in nine subtypes with each having its own specific trigger. These subtypes are further divided in physical urticarias (symptomatic dermographism, cold urticaria, delayed pressure urticaria, solar urticaria, heat urticaria, vibratory angioedema) or non-physical urticarias, i.e., cholinergic urticaria, aquagenic urticaria, and contact urticaria. Symptomatic dermographism (SD) is the most prevalent subtype of the physical urticarias. Its prevalence in Western populations is estimated to be between 1-5%. Following SD, cold urticaria (ColdU) is the next most common form, its annual incidence is estimated to be 0.05%. In this study, patients with the ColdU and symptomatic SD subtypes will be enrolled. As of yet, disease diagnosis of SD and ColdU is mostly purely clinical (clinical picture + patients' history), as there is a lack of objective biomarkers. Currently only two objective tools are available for the diagnosis of SD and ColdU, which are the FricTest and Temptest (both provocation tests). In addition, there is a lack of objective biomarkers for the prediction of treatment response and for the monitoring of treatment effects, as this is nowadays only monitored by patient reported outcomes.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07359430
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Skin Diseases
Currently open trials in the same condition.
- NCT07412691 — A Study to Evaluate the Safety of BG-A3004 in Healthy Participants and Patients With Immune-Mediated Skin Diseases · Phase 1 · recruiting
- NCT07091604 — An Observational Study to Assess Objective Skin Pigmentation Variation. · recruiting
- NCT07158879 — Skin Reactions Related to Thoracic Implantable Chamber Dressings · recruiting
- NCT06850311 — Herbal Ointment in Treating Atopic Dermatitis Topically · Phase 2, PHASE3 · recruiting
- NCT06563323 — Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG) · Phase 2 · recruiting
Other Centre for Human Drug Research, Netherlands trials
Trials by the same sponsor.
- NCT05827107 — Skin Barrier and Microbiome of CTCL Patients · completed
- NCT05303480 — Deep Phenotyping of Cutaneous T Cell Lymphoma, Type Mycosis Fungoides · NA · completed
- NCT04394936 — An Explorative Psoriasis Biomarker Study · NA · terminated
- NCT04829396 — Effect of Fibre Supplementation on Mixed-meal Challenge Response · NA · completed
- NCT04999735 — Digital Biotyping of FSHD Patients and Controls · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07359430 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre for Human Drug Research, Netherlands
- Last refreshed: 22 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07359430.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing